Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Could a vitamin d boost strengthen bones and mobility after neurological injury?

NCT ID NCT06791044

Disease control Sponsor: Dionyssiotis, Yannis, M.D. Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now This study
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jul 31, 2026 · Last updated Jul 31, 2026

Summary

This trial is testing whether vitamin D supplements can improve bone density, body composition, strength, walking speed, and physical performance in people hospitalized with neurological disorders like stroke, spinal cord injury, or traumatic brain injury. Participants will receive one of two vitamin D dosing plans over 8 weeks, while researchers track changes in these health measures and pain levels. The study also includes healthy controls for comparison, aiming to understand how common vitamin D insufficiency is in this population and whether supplementation helps.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
Vitamin D (cholecalciferol) supplements at two dosing schedules
What this could lead to
If vitamin D supplementation improves bone density, strength, and physical performance in people with neurological disabilities, it could point to a simple, low-cost way to enhance their quality of life and reduce fracture risk.
What could go wrong
This is a relatively small trial, and results may not apply to all neurological patients. Vitamin D may not significantly improve the measured outcomes, and high doses could carry risks like elevated calcium levels.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

About 120 people

The number the study aims to enrol. It can still change while the study runs.

Started

Sep 2025

Expected to finish

Dec 2027

An estimate. End dates often move.

Lead sponsor

An individual researcher

The lead sponsor is a named person rather than an organisation.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

20 to 85 years

Sex

Anyone

Healthy volunteers

Accepted

You do not need to have the condition being studied to take part.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * populations with neurological disorders * healthy volunteers (controls) Exclusion Criteria: * The subject is excluded if they: * are legally or mentally incapable of comprehending and consenting to participate in the study * have a history of or exhibit indicators of metabolic bone disease, including the following: Hypoparathyroidism, primary hyperparathyroidism, recent hyperthyroidism (within the last six months), Paget's disease of bone; * grade 3 or 4 pressure ulcers present; * has undergone treatment with pharmacological agents influencing bone metabolism prior to the initial bone density assessment, including the following: bisphosphonates in the year prior to the bone density assessment ; parathyroid hormone in the year prior to the research ; estrogens, selective estrogen receptor modulators (SERMs), tibolone, or anabolic steroids within the preceding six months. * Thyroid drugs are permissible only if the dosage has remained consistent for the preceding six weeks and TSH levels are within the normal range. * Corticosteroid medication exceeding 7.5 mg of prednisone orally per day for a duration exceeding one month within the past six months. * Immunosuppressant therapy within the past year; * Vitamin A therapy above 10,000 IU per day or Vitamin D exceeding 5,000 IU per day. * Participants are prohibited from consuming additional vitamin D supplements exceeding 400 IU per day or traveling to regions with heightened sunshine exposure during the trial.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Spinal cord injury are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

osteoporosis Pain Sarcopenia spinal cord injury stroke disorder traumatic brain injury vitamin D deficiency

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Vitamin D insufficiency

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    2 sites. The list below names each one and where it is.

  2. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • National Rehabilitation Center EKA

    RECRUITING

    Nea Liosia, Athens, 13122, Greece

  • National Rehabilitation Center EKA (Ethniko Kentro Apokatastasis)

    RECRUITING

    Athens, Attica, 13122, Greece

More trials for these conditions

Other studies related to the condition(s) this trial covers.